###begin article-title 0
Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes
###end article-title 0
###begin title 1
Aims/hypothesis
###end title 1
###begin p 2
###xml 263 271 <span type="species:ncbi:9606">patients</span>
###xml 556 564 <span type="species:ncbi:9606">patients</span>
Type 1 diabetes is a proinflammatory state characterised by increased levels of circulating biomarkers of inflammation and monocyte activity. We have shown increased Toll-like receptor 2 (TLR2) and TLR4 expression and signalling in monocytes from type 1 diabetic patients. Several endogenous ligands of TLR2 and TLR4 have been identified; however, there is a paucity of data on levels of these endogenous ligands in diabetes. Thus, the aim of this study was to examine circulating levels of exogenous/endogenous ligands of TLR2 and TLR4 in type 1 diabetic patients and to compare these with the levels in matched healthy controls.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 18 19 18 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 56 57 56 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 46 54 <span type="species:ncbi:9606">patients</span>
Healthy controls (n = 37) and type 1 diabetic patients (n = 34) were recruited, and a fasting blood sample was obtained. Circulating levels of endotoxin, heat-shock protein 60 (Hsp60), high-mobility group box 1 (HMGB1) and growth arrest-specific 6 (GAS6) proteins were assessed by ELISA, and TLR2 and TLR4 expression was determined by flow cytometry.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 227 228 227 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 240 241 240 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 95 103 <span type="species:ncbi:9606">patients</span>
###xml 217 225 <span type="species:ncbi:9606">patients</span>
Levels of the classical TLR4 ligand, endotoxin, were significantly elevated in type 1 diabetic patients compared with those in matched controls. Hsp60 and HMGB1 concentrations were also significantly increased in the patients (p < 0.01 and p < 0.001, respectively). No significant differences were observed in GAS6.
###end p 6
###begin title 7
Conclusions/interpretation
###end title 7
###begin p 8
We report the novel observation that levels of ligands of TLR2 and TLR4 are significantly elevated in type 1 diabetes, and this, in concert with hyperglycaemia, accounts for the increase in TLR2 and TLR4 activity, underscoring the proinflammatory state of type 1 diabetes.
###end p 8
###begin title 9
Keywords
###end title 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 96 97 96 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 175 176 175 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 267 268 267 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 343 344 343 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 524 525 524 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 474 482 <span type="species:ncbi:9606">patients</span>
Type 1 diabetes is associated with an increased risk of micro- and macrovascular complications [1]. Recent studies have shown that type 1 diabetes is a proinflammatory state [2]. Members of the Toll-like receptor (TLR) family play a critical role in innate immunity [3]. The TLRs, TLR2 and TLR4 also play an important role in atherosclerosis [3]. We recently demonstrated increased levels of TLR2 and TLR4 expression, activity and signalling in monocytes of type 1 diabetic patients compared with those in matched controls [4].
###end p 11
###begin p 12
###xml 92 93 92 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 393 394 393 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 569 570 569 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 616 620 616 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tlr4</italic>
###xml 765 766 765 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 1035 1036 1035 1036 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 1364 1365 1364 1365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 1746 1747 1746 1747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 604 608 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 673 678 <span type="species:ncbi:9606">human</span>
###xml 1630 1638 <span type="species:ncbi:9606">patients</span>
A number of endogenous molecules may also be potent activators of the innate immune system [5] and are capable of inducing the release of proinflammatory cytokines from monocytes/macrophages via the TLR signal-transduction pathways. However, there are limited data on levels of endogenous ligands of TLR2 and TLR4 in type 1 diabetes. The major ligand involved in TLR4 activation is endotoxin [5]. The activation of these TLR2 and TLR4 on monocytes leads to the production of cytokines and chemokines. Heat shock proteins (hsps) are endogenous ligands of TLR2 and TLR4 [6]. Using macrophages from C3H/HeJ mice with a Tlr4 point mutation, the cytokine effects of recombinant human Hsp60 were shown to be dependent on TLR4, suggesting that Hsp60 may be a TLR4 ligand [6]. High-mobility group box 1 (HMGB1) protein has been reported to be a 'late' proinflammatory mediator in sepsis. HMGB1 can induce activation of intracellular signalling pathways via activation of TLR2, TLR4 and the receptor for advanced glycation end-products (RAGE) [7]. Extracellular HMGB1 thus acts as an alarmin and can activate the innate system and function in a synergistic fashion with other proinflammatory mediators to induce responses. Growth arrest-specific 6 (GAS6) protein is another endogenous ligand of TLR2 and TLR4 that is induced in experimental models of diabetic nephropathy [8]. Thus, in this study, since type 1 diabetes has previously been shown to be a proinflammatory state involving increased TLR2 and TLR4 expression, we determined the levels of endogenous (Hsp60, HMGB1 and GAS6) and exogenous (endotoxin) ligands of TLR2 and TLR4 in patients with type 1 diabetes and compared these with the levels in matched healthy controls. In a previous report [4], we examined myeloid differentiation response 88 (MyD88)-dependent TLR activation, and we follow up this work in the present study by examining levels of interferon-beta (IFNbeta), a biological indicator of non-MyD88-dependent activation of TLRs.
###end p 12
###begin title 13
Methods
###end title 13
###begin p 14
###xml 26 27 26 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 16 24 <span type="species:ncbi:9606">patients</span>
###xml 243 251 <span type="species:ncbi:9606">patients</span>
Type 1 diabetic patients (n = 34) (aged < 20 years at onset and on insulin therapy since diagnosis) with a duration of diabetes of >/=1 year were recruited from the diabetes/pediatric clinics at UC Davis Medical Center and advertisements. All patients were aged >/=18 years at recruitment and none was receiving metformin and/or thiazolidinediones, or any anti-inflammatory therapy.
###end p 14
###begin p 15
###xml 18 19 18 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 283 284 283 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 322 334 <span type="species:ncbi:9606">participants</span>
###xml 439 450 <span type="species:ncbi:9606">participant</span>
Healthy controls (n = 37) aged >18 years were included if they had a normal complete blood count, no family history of diabetes or other chronic diseases, normal kidney, liver, thyroid function and fasting plasma glucose <5.5 mmol/l. Selection criteria were as described previously [4]. Informed consent was obtained from participants in the study, which was approved by the Institutional Review Board at UC Davis Medical Center. For each participant, a medical history was obtained, a physical examination was undertaken, and then a fasting blood sample (30 ml) was collected. Routine laboratory tests were performed in the clinical pathology laboratory.
###end p 15
###begin p 16
###xml 208 209 208 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 539 540 539 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 309 317 <span type="species:ncbi:9606">patients</span>
###xml 343 348 <span type="species:ncbi:9606">human</span>
###xml 810 818 <span type="species:ncbi:9606">patients</span>
Mononuclear cells were isolated from the heparinised blood samples by Ficoll-Hypaque centrifugation followed by negative magnetic separation using the depletion technique (Miltenyi Biotech, Auburn, CA, USA) [4]. The purity of the isolated mononuclear cells was 88%. Monocytes from control and type 1 diabetic patients were incubated with anti-human TLR2 and TLR4 antibodies (Invivogen, San Diego, CA, USA) or isotype controls, and surface expression of TLR2 and TLR4 was analysed using BD FACSArray (Becton-Dickinson, Fullerton, CA, USA) [4]. Results were expressed as mean fluorescence intensity of 10,000 cells (mfi). The intra- and inter-assay CVs for TLR2 and TLR4 expression were both found to be <5% and <15%, respectively. Endotoxin levels were measured in serum samples of controls and type 1 diabetic patients by the Limulus amoebocyte lysate assay (Invivogen). Sandwich ELISA was used to assess levels of IFNbeta (R&D, Minneapolis, MN, USA), HMGB1 (Shino Test, Tokyo, Japan), Hsp60 (Assay Designs, Ann Arbor, MI, USA) and GAS6 (R&D, Minneapolis, MN, USA); the intra-assay CV for each of these assays was <10%.
###end p 16
###begin p 17
###xml 258 259 256 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 337 338 335 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Statistical analyses were performed using SAS (SAS Institute, Cary, NC, USA). Data are expressed as the mean +/- SD for parametric data and as the median and interquartile range for non-parametric data. Parametric data were analysed using paired, two-tailed t tests; non-parametric data were analysed using Wilcoxon signed rank tests. A p value of less than 0.05 was considered significant. Spearman's rank correlation was computed to assess associations between variables.
###end p 17
###begin title 18
Results
###end title 18
###begin p 19
###xml 169 171 169 171 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1c</sub>
###xml 250 251 250 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 254 261 254 261 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 261 308 261 308 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="20">Characteristics of the participants at baseline</p>
###xml 261 308 261 308 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="20">Characteristics of the participants at baseline</p></caption>
###xml 308 308 308 308 <th xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 318 319 318 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 308 325 308 325 <th xmlns:xlink="http://www.w3.org/1999/xlink">Controls (<italic>n</italic>&#8201;=&#8201;37)</th>
###xml 342 343 342 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 325 349 325 349 <th xmlns:xlink="http://www.w3.org/1999/xlink">Type 1 diabetes (<italic>n</italic>&#8201;=&#8201;34)</th>
###xml 308 349 308 349 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th/><th>Controls (<italic>n</italic>&#8201;=&#8201;37)</th><th>Type 1 diabetes (<italic>n</italic>&#8201;=&#8201;34)</th></tr>
###xml 308 349 308 349 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th/><th>Controls (<italic>n</italic>&#8201;=&#8201;37)</th><th>Type 1 diabetes (<italic>n</italic>&#8201;=&#8201;34)</th></tr></thead>
###xml 349 360 349 360 <td xmlns:xlink="http://www.w3.org/1999/xlink">Age (years)</td>
###xml 360 369 360 367 <td xmlns:xlink="http://www.w3.org/1999/xlink">34&#8201;&#177;&#8201;11</td>
###xml 369 378 367 374 <td xmlns:xlink="http://www.w3.org/1999/xlink">32&#8201;&#177;&#8201;11</td>
###xml 349 378 349 374 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Age (years)</td><td>34&#8201;&#177;&#8201;11</td><td>32&#8201;&#177;&#8201;11</td></tr>
###xml 387 388 383 384 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 378 389 374 385 <td xmlns:xlink="http://www.w3.org/1999/xlink">BMI (kg/m<sup>2</sup>)</td>
###xml 389 397 385 391 <td xmlns:xlink="http://www.w3.org/1999/xlink">24&#8201;&#177;&#8201;4</td>
###xml 397 405 391 397 <td xmlns:xlink="http://www.w3.org/1999/xlink">25&#8201;&#177;&#8201;4</td>
###xml 378 405 374 397 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>BMI (kg/m<sup>2</sup>)</td><td>24&#8201;&#177;&#8201;4</td><td>25&#8201;&#177;&#8201;4</td></tr>
###xml 405 422 397 414 <td xmlns:xlink="http://www.w3.org/1999/xlink">Male/female ratio</td>
###xml 422 427 414 419 <td xmlns:xlink="http://www.w3.org/1999/xlink">19:18</td>
###xml 427 432 419 424 <td xmlns:xlink="http://www.w3.org/1999/xlink">15:19</td>
###xml 405 432 397 424 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Male/female ratio</td><td>19:18</td><td>15:19</td></tr>
###xml 432 448 424 440 <td xmlns:xlink="http://www.w3.org/1999/xlink">Glucose (mmol/l)</td>
###xml 448 459 440 449 <td xmlns:xlink="http://www.w3.org/1999/xlink">4.9&#8201;&#177;&#8201;0.5</td>
###xml 459 471 449 459 <td xmlns:xlink="http://www.w3.org/1999/xlink">7.2&#8201;&#177;&#8201;3.8*</td>
###xml 432 471 424 459 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Glucose (mmol/l)</td><td>4.9&#8201;&#177;&#8201;0.5</td><td>7.2&#8201;&#177;&#8201;3.8*</td></tr>
###xml 474 476 462 464 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1c</sub>
###xml 471 480 459 468 <td xmlns:xlink="http://www.w3.org/1999/xlink">HbA<sub>1c</sub> (%)</td>
###xml 480 491 468 477 <td xmlns:xlink="http://www.w3.org/1999/xlink">5.4&#8201;&#177;&#8201;0.4</td>
###xml 491 503 477 487 <td xmlns:xlink="http://www.w3.org/1999/xlink">7.9&#8201;&#177;&#8201;1.4*</td>
###xml 471 503 459 487 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>HbA<sub>1c</sub> (%)</td><td>5.4&#8201;&#177;&#8201;0.4</td><td>7.9&#8201;&#177;&#8201;1.4*</td></tr>
###xml 503 529 487 513 <td xmlns:xlink="http://www.w3.org/1999/xlink">Total cholesterol (mmol/l)</td>
###xml 529 540 513 522 <td xmlns:xlink="http://www.w3.org/1999/xlink">4.5&#8201;&#177;&#8201;0.8</td>
###xml 540 551 522 531 <td xmlns:xlink="http://www.w3.org/1999/xlink">4.7&#8201;&#177;&#8201;0.8</td>
###xml 503 551 487 531 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Total cholesterol (mmol/l)</td><td>4.5&#8201;&#177;&#8201;0.8</td><td>4.7&#8201;&#177;&#8201;0.8</td></tr>
###xml 551 575 531 555 <td xmlns:xlink="http://www.w3.org/1999/xlink">Triacylglycerol (mmol/l)</td>
###xml 575 586 555 564 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.9&#8201;&#177;&#8201;0.4</td>
###xml 586 597 564 573 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.9&#8201;&#177;&#8201;0.5</td>
###xml 551 597 531 573 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Triacylglycerol (mmol/l)</td><td>0.9&#8201;&#177;&#8201;0.4</td><td>0.9&#8201;&#177;&#8201;0.5</td></tr>
###xml 597 621 573 597 <td xmlns:xlink="http://www.w3.org/1999/xlink">LDL-cholesterol (mmol/l)</td>
###xml 621 632 597 606 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.9&#8201;&#177;&#8201;0.6</td>
###xml 632 643 606 615 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.9&#8201;&#177;&#8201;0.6</td>
###xml 597 643 573 615 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>LDL-cholesterol (mmol/l)</td><td>2.9&#8201;&#177;&#8201;0.6</td><td>2.9&#8201;&#177;&#8201;0.6</td></tr>
###xml 643 667 615 639 <td xmlns:xlink="http://www.w3.org/1999/xlink">HDL-cholesterol (mmol/l)</td>
###xml 667 678 639 648 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.1&#8201;&#177;&#8201;0.4</td>
###xml 678 689 648 657 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.3&#8201;&#177;&#8201;0.4</td>
###xml 643 689 615 657 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>HDL-cholesterol (mmol/l)</td><td>1.1&#8201;&#177;&#8201;0.4</td><td>1.3&#8201;&#177;&#8201;0.4</td></tr>
###xml 349 689 349 657 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Age (years)</td><td>34&#8201;&#177;&#8201;11</td><td>32&#8201;&#177;&#8201;11</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>24&#8201;&#177;&#8201;4</td><td>25&#8201;&#177;&#8201;4</td></tr><tr><td>Male/female ratio</td><td>19:18</td><td>15:19</td></tr><tr><td>Glucose (mmol/l)</td><td>4.9&#8201;&#177;&#8201;0.5</td><td>7.2&#8201;&#177;&#8201;3.8*</td></tr><tr><td>HbA<sub>1c</sub> (%)</td><td>5.4&#8201;&#177;&#8201;0.4</td><td>7.9&#8201;&#177;&#8201;1.4*</td></tr><tr><td>Total cholesterol (mmol/l)</td><td>4.5&#8201;&#177;&#8201;0.8</td><td>4.7&#8201;&#177;&#8201;0.8</td></tr><tr><td>Triacylglycerol (mmol/l)</td><td>0.9&#8201;&#177;&#8201;0.4</td><td>0.9&#8201;&#177;&#8201;0.5</td></tr><tr><td>LDL-cholesterol (mmol/l)</td><td>2.9&#8201;&#177;&#8201;0.6</td><td>2.9&#8201;&#177;&#8201;0.6</td></tr><tr><td>HDL-cholesterol (mmol/l)</td><td>1.1&#8201;&#177;&#8201;0.4</td><td>1.3&#8201;&#177;&#8201;0.4</td></tr></tbody>
###xml 308 689 308 657 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th/><th>Controls (<italic>n</italic>&#8201;=&#8201;37)</th><th>Type 1 diabetes (<italic>n</italic>&#8201;=&#8201;34)</th></tr></thead><tbody><tr><td>Age (years)</td><td>34&#8201;&#177;&#8201;11</td><td>32&#8201;&#177;&#8201;11</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>24&#8201;&#177;&#8201;4</td><td>25&#8201;&#177;&#8201;4</td></tr><tr><td>Male/female ratio</td><td>19:18</td><td>15:19</td></tr><tr><td>Glucose (mmol/l)</td><td>4.9&#8201;&#177;&#8201;0.5</td><td>7.2&#8201;&#177;&#8201;3.8*</td></tr><tr><td>HbA<sub>1c</sub> (%)</td><td>5.4&#8201;&#177;&#8201;0.4</td><td>7.9&#8201;&#177;&#8201;1.4*</td></tr><tr><td>Total cholesterol (mmol/l)</td><td>4.5&#8201;&#177;&#8201;0.8</td><td>4.7&#8201;&#177;&#8201;0.8</td></tr><tr><td>Triacylglycerol (mmol/l)</td><td>0.9&#8201;&#177;&#8201;0.4</td><td>0.9&#8201;&#177;&#8201;0.5</td></tr><tr><td>LDL-cholesterol (mmol/l)</td><td>2.9&#8201;&#177;&#8201;0.6</td><td>2.9&#8201;&#177;&#8201;0.6</td></tr><tr><td>HDL-cholesterol (mmol/l)</td><td>1.1&#8201;&#177;&#8201;0.4</td><td>1.3&#8201;&#177;&#8201;0.4</td></tr></tbody></table>
###xml 689 722 657 688 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="21">Data are expressed as mean&#8201;&#177;&#8201;SD</p>
###xml 723 724 689 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 722 743 688 709 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="22">*<italic>p</italic>&#8201;&lt;&#8201;0.05 vs controls</p>
###xml 689 743 657 709 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="21">Data are expressed as mean&#8201;&#177;&#8201;SD</p><p textid="22">*<italic>p</italic>&#8201;&lt;&#8201;0.05 vs controls</p></table-wrap-foot>
###xml 254 743 254 709 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="20">Characteristics of the participants at baseline</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Controls (<italic>n</italic>&#8201;=&#8201;37)</th><th>Type 1 diabetes (<italic>n</italic>&#8201;=&#8201;34)</th></tr></thead><tbody><tr><td>Age (years)</td><td>34&#8201;&#177;&#8201;11</td><td>32&#8201;&#177;&#8201;11</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>24&#8201;&#177;&#8201;4</td><td>25&#8201;&#177;&#8201;4</td></tr><tr><td>Male/female ratio</td><td>19:18</td><td>15:19</td></tr><tr><td>Glucose (mmol/l)</td><td>4.9&#8201;&#177;&#8201;0.5</td><td>7.2&#8201;&#177;&#8201;3.8*</td></tr><tr><td>HbA<sub>1c</sub> (%)</td><td>5.4&#8201;&#177;&#8201;0.4</td><td>7.9&#8201;&#177;&#8201;1.4*</td></tr><tr><td>Total cholesterol (mmol/l)</td><td>4.5&#8201;&#177;&#8201;0.8</td><td>4.7&#8201;&#177;&#8201;0.8</td></tr><tr><td>Triacylglycerol (mmol/l)</td><td>0.9&#8201;&#177;&#8201;0.4</td><td>0.9&#8201;&#177;&#8201;0.5</td></tr><tr><td>LDL-cholesterol (mmol/l)</td><td>2.9&#8201;&#177;&#8201;0.6</td><td>2.9&#8201;&#177;&#8201;0.6</td></tr><tr><td>HDL-cholesterol (mmol/l)</td><td>1.1&#8201;&#177;&#8201;0.4</td><td>1.3&#8201;&#177;&#8201;0.4</td></tr></tbody></table><table-wrap-foot><p textid="21">Data are expressed as mean&#8201;&#177;&#8201;SD</p><p textid="22">*<italic>p</italic>&#8201;&lt;&#8201;0.05 vs controls</p></table-wrap-foot></table-wrap>
###xml 217 225 <span type="species:ncbi:9606">patients</span>
###xml 284 296 <span type="species:ncbi:9606">participants</span>
There were no significant differences between the control and type 1 diabetic groups in terms of age, BMI, male/female ratio and lipid profile. Levels of glucose and HbA1c were significantly higher in type 1 diabetic patients than in controls (Table 1). Table 1Characteristics of the participants at baselineControls (n = 37)Type 1 diabetes (n = 34)Age (years)34 +/- 1132 +/- 11BMI (kg/m2)24 +/- 425 +/- 4Male/female ratio19:1815:19Glucose (mmol/l)4.9 +/- 0.57.2 +/- 3.8*HbA1c (%)5.4 +/- 0.47.9 +/- 1.4*Total cholesterol (mmol/l)4.5 +/- 0.84.7 +/- 0.8Triacylglycerol (mmol/l)0.9 +/- 0.40.9 +/- 0.5LDL-cholesterol (mmol/l)2.9 +/- 0.62.9 +/- 0.6HDL-cholesterol (mmol/l)1.1 +/- 0.41.3 +/- 0.4Data are expressed as mean +/- SD*p < 0.05 vs controls
###end p 19
###begin p 20
###xml 23 35 <span type="species:ncbi:9606">participants</span>
Characteristics of the participants at baseline
###end p 20
###begin p 21
Data are expressed as mean +/- SD
###end p 21
###begin p 22
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
*p < 0.05 vs controls
###end p 22
###begin p 23
###xml 158 159 158 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 222 223 222 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 235 236 235 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 502 503 495 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 513 520 506 513 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 520 554 513 547 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="24">Levels of ligands of TLR2 and TLR4</p>
###xml 520 554 513 547 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="24">Levels of ligands of TLR2 and TLR4</p></caption>
###xml 554 554 547 547 <th xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 564 565 557 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 554 571 547 564 <th xmlns:xlink="http://www.w3.org/1999/xlink">Controls (<italic>n</italic>&#8201;=&#8201;37)</th>
###xml 588 589 581 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 571 595 564 588 <th xmlns:xlink="http://www.w3.org/1999/xlink">Type 1 diabetes (<italic>n</italic>&#8201;=&#8201;34)</th>
###xml 554 595 547 588 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th/><th>Controls (<italic>n</italic>&#8201;=&#8201;37)</th><th>Type 1 diabetes (<italic>n</italic>&#8201;=&#8201;34)</th></tr>
###xml 554 595 547 588 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th/><th>Controls (<italic>n</italic>&#8201;=&#8201;37)</th><th>Type 1 diabetes (<italic>n</italic>&#8201;=&#8201;34)</th></tr></thead>
###xml 595 613 588 606 <td xmlns:xlink="http://www.w3.org/1999/xlink">Endotoxin (nmol/l)</td>
###xml 613 626 606 617 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">2.53&#8201;&#177;&#8201;0.67</td>
###xml 626 641 617 630 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">3.32&#8201;&#177;&#8201;0.82**</td>
###xml 595 641 588 630 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Endotoxin (nmol/l)</td><td char="&#177;" align="char">2.53&#8201;&#177;&#8201;0.67</td><td char="&#177;" align="char">3.32&#8201;&#177;&#8201;0.82**</td></tr>
###xml 641 655 630 644 <td xmlns:xlink="http://www.w3.org/1999/xlink">HMGB1 (nmol/l)</td>
###xml 655 668 644 655 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">0.13&#8201;&#177;&#8201;0.04</td>
###xml 668 683 655 668 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">0.20&#8201;&#177;&#8201;0.06**</td>
###xml 641 683 630 668 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>HMGB1 (nmol/l)</td><td char="&#177;" align="char">0.13&#8201;&#177;&#8201;0.04</td><td char="&#177;" align="char">0.20&#8201;&#177;&#8201;0.06**</td></tr>
###xml 683 697 668 682 <td xmlns:xlink="http://www.w3.org/1999/xlink">Hsp60 (pmol/l)</td>
###xml 697 709 682 692 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">18.5&#8201;&#177;&#8201;5.0</td>
###xml 709 723 692 704 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">23.2&#8201;&#177;&#8201;6.7**</td>
###xml 683 723 668 704 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Hsp60 (pmol/l)</td><td char="&#177;" align="char">18.5&#8201;&#177;&#8201;5.0</td><td char="&#177;" align="char">23.2&#8201;&#177;&#8201;6.7**</td></tr>
###xml 723 736 704 717 <td xmlns:xlink="http://www.w3.org/1999/xlink">GAS6 (nmol/l)</td>
###xml 736 748 717 727 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">11.2&#8201;&#177;&#8201;6.9</td>
###xml 748 760 727 737 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">10.2&#8201;&#177;&#8201;5.9</td>
###xml 723 760 704 737 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>GAS6 (nmol/l)</td><td char="&#177;" align="char">11.2&#8201;&#177;&#8201;6.9</td><td char="&#177;" align="char">10.2&#8201;&#177;&#8201;5.9</td></tr>
###xml 595 760 588 737 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Endotoxin (nmol/l)</td><td char="&#177;" align="char">2.53&#8201;&#177;&#8201;0.67</td><td char="&#177;" align="char">3.32&#8201;&#177;&#8201;0.82**</td></tr><tr><td>HMGB1 (nmol/l)</td><td char="&#177;" align="char">0.13&#8201;&#177;&#8201;0.04</td><td char="&#177;" align="char">0.20&#8201;&#177;&#8201;0.06**</td></tr><tr><td>Hsp60 (pmol/l)</td><td char="&#177;" align="char">18.5&#8201;&#177;&#8201;5.0</td><td char="&#177;" align="char">23.2&#8201;&#177;&#8201;6.7**</td></tr><tr><td>GAS6 (nmol/l)</td><td char="&#177;" align="char">11.2&#8201;&#177;&#8201;6.9</td><td char="&#177;" align="char">10.2&#8201;&#177;&#8201;5.9</td></tr></tbody>
###xml 554 760 547 737 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th/><th>Controls (<italic>n</italic>&#8201;=&#8201;37)</th><th>Type 1 diabetes (<italic>n</italic>&#8201;=&#8201;34)</th></tr></thead><tbody><tr><td>Endotoxin (nmol/l)</td><td char="&#177;" align="char">2.53&#8201;&#177;&#8201;0.67</td><td char="&#177;" align="char">3.32&#8201;&#177;&#8201;0.82**</td></tr><tr><td>HMGB1 (nmol/l)</td><td char="&#177;" align="char">0.13&#8201;&#177;&#8201;0.04</td><td char="&#177;" align="char">0.20&#8201;&#177;&#8201;0.06**</td></tr><tr><td>Hsp60 (pmol/l)</td><td char="&#177;" align="char">18.5&#8201;&#177;&#8201;5.0</td><td char="&#177;" align="char">23.2&#8201;&#177;&#8201;6.7**</td></tr><tr><td>GAS6 (nmol/l)</td><td char="&#177;" align="char">11.2&#8201;&#177;&#8201;6.9</td><td char="&#177;" align="char">10.2&#8201;&#177;&#8201;5.9</td></tr></tbody></table>
###xml 760 793 737 768 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="25">Data are expressed as mean&#8201;&#177;&#8201;SD</p>
###xml 795 796 770 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 793 815 768 790 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="26">**<italic>p</italic>&#8201;&lt;&#8201;0.01 vs controls</p>
###xml 760 815 737 790 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="25">Data are expressed as mean&#8201;&#177;&#8201;SD</p><p textid="26">**<italic>p</italic>&#8201;&lt;&#8201;0.01 vs controls</p></table-wrap-foot>
###xml 513 815 506 790 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="24">Levels of ligands of TLR2 and TLR4</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Controls (<italic>n</italic>&#8201;=&#8201;37)</th><th>Type 1 diabetes (<italic>n</italic>&#8201;=&#8201;34)</th></tr></thead><tbody><tr><td>Endotoxin (nmol/l)</td><td char="&#177;" align="char">2.53&#8201;&#177;&#8201;0.67</td><td char="&#177;" align="char">3.32&#8201;&#177;&#8201;0.82**</td></tr><tr><td>HMGB1 (nmol/l)</td><td char="&#177;" align="char">0.13&#8201;&#177;&#8201;0.04</td><td char="&#177;" align="char">0.20&#8201;&#177;&#8201;0.06**</td></tr><tr><td>Hsp60 (pmol/l)</td><td char="&#177;" align="char">18.5&#8201;&#177;&#8201;5.0</td><td char="&#177;" align="char">23.2&#8201;&#177;&#8201;6.7**</td></tr><tr><td>GAS6 (nmol/l)</td><td char="&#177;" align="char">11.2&#8201;&#177;&#8201;6.9</td><td char="&#177;" align="char">10.2&#8201;&#177;&#8201;5.9</td></tr></tbody></table><table-wrap-foot><p textid="25">Data are expressed as mean&#8201;&#177;&#8201;SD</p><p textid="26">**<italic>p</italic>&#8201;&lt;&#8201;0.01 vs controls</p></table-wrap-foot></table-wrap>
###xml 106 114 <span type="species:ncbi:9606">patients</span>
###xml 417 425 <span type="species:ncbi:9606">patients</span>
Levels of the major exogenous ligand for TLR4, endotoxin, were significantly increased in type 1 diabetic patients compared with those in the controls (Table 2). Levels of Hsp60 and HMGB1 were also significantly elevated (p < 0.01 and p < 0.001, respectively). There was no significant difference between the two groups with respect to GAS6 levels. IFNbeta concentrations were significantly higher in type 1 diabetic patients compared with controls (43.9 +/- 10.3 vs 26.7 +/- 3.2 nmol/l, respectively, p < 0.05). Table 2Levels of ligands of TLR2 and TLR4Controls (n = 37)Type 1 diabetes (n = 34)Endotoxin (nmol/l)2.53 +/- 0.673.32 +/- 0.82**HMGB1 (nmol/l)0.13 +/- 0.040.20 +/- 0.06**Hsp60 (pmol/l)18.5 +/- 5.023.2 +/- 6.7**GAS6 (nmol/l)11.2 +/- 6.910.2 +/- 5.9Data are expressed as mean +/- SD**p < 0.01 vs controls
###end p 23
###begin p 24
Levels of ligands of TLR2 and TLR4
###end p 24
###begin p 25
Data are expressed as mean +/- SD
###end p 25
###begin p 26
###xml 2 3 2 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
**p < 0.01 vs controls
###end p 26
###begin p 27
###xml 103 104 103 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 113 114 113 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 246 247 246 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 256 257 256 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 314 315 314 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 324 325 324 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 384 385 384 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 394 395 394 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 415 416 415 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 425 426 425 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 550 551 550 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 560 561 560 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 625 627 625 627 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1c</sub>
###xml 643 644 643 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 653 654 653 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Across the study sample as a whole, there was a significant correlation between TLR2 and HMGB1 levels (r = 0.42, p < 0.05), a trend towards a positive correlation between TLR2 and Hsp60 levels (though this did not reach statistical significance; r = 0.33, p < 0.09), and no correlation between TLR2 and endotoxin (r = 0.34, p > 0.2). TLR4 was significantly correlated with endotoxin (r = 0.56, p < 0.01) and Hsp60 (r = 0.61, p < 0.01), and showed a trend towards a positive correlation with HMGB1 (though this did not reach statistical significance; r = 0.39, p < 0.1). The only ligand to be significantly correlated with HbA1c was endotoxin (r = 0.64, p < 0.01).
###end p 27
###begin title 28
Discussion
###end title 28
###begin p 29
###xml 92 93 92 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 199 200 199 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 438 439 427 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 624 625 606 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 719 720 701 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 189 197 <span type="species:ncbi:9606">patients</span>
###xml 542 550 <span type="species:ncbi:9606">patients</span>
In addition to regulating inflammation, both TLR2 and TLR4 are relevant to atherosclerosis [3]. The expression and activity of TLR2 and TLR4 are increased in monocytes from type 1 diabetic patients [4]. Downstream targets of TLR, nuclear factor-kappaB (NF-kappaB), MyD88, TIR-domain-containing adapter-inducing IFN-beta (TRIF) and phosphorylated IL-1 receptor-associated kinase (pIRAK), were significantly upregulated in type 1 diabetes [4]. The release of IL-1beta and TNF-alpha from monocytes was significantly increased in type 1 diabetic patients compared with controls and was correlated with TLR2 and TLR4 expression [4]. Also, high glucose levels upregulate, and insulin downregulates, TLR2 and TLR4 expression [9].
###end p 29
###begin p 30
###xml 325 327 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 555 557 555 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 224 232 <span type="species:ncbi:9606">patients</span>
Given the importance of TLR2 and TLR4 in atherosclerosis and their emerging role in the proinflammatory state of type 1 diabetes, in this study we examined circulating levels of several different ligands of TLR2 and TLR4 in patients with type 1 diabetes and compared these with the levels in matched controls. Creely et al. [10] have previously shown increased levels of endotoxin in type 2 diabetes but not increased TLR4 expression in adipose tissue. Furthermore, they demonstrated that circulating endotoxin levels are associated with atherosclerosis [10]. In this report, we provide evidence of increased endotoxin levels, which could contribute to the proinflammatory burden by activation of TLR4 and downstream signalling pathways.
###end p 30
###begin p 31
###xml 107 108 107 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 154 162 <span type="species:ncbi:9606">patients</span>
The hsps such as Hsp60 induce the production of proinflammatory cytokines via activation of TLR2 and TLR4 [6]. In this paper we show that type 1 diabetic patients also have high circulating levels of Hsp60, which could trigger the activation of TLR2 and TLR4, leading to a proinflammatory state.
###end p 31
###begin p 32
###xml 268 269 268 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 323 331 <span type="species:ncbi:9606">patients</span>
HMGB1 induces the activation of intracellular signalling pathways via interaction with at least three pattern-recognition receptors: TLR2, TLR4 and RAGE. Furthermore, HMGB1 stimulates the transcription of genes encoding proteins involved in the proinflammatory state [7]. In the present study, we show that type 1 diabetic patients have high circulating levels of HMGB1, which could trigger TLR2 and TLR4 activation, leading to a proinflammatory state.
###end p 32
###begin p 33
###xml 238 239 230 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 360 361 349 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 387 388 376 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 470 478 <span type="species:ncbi:9606">patients</span>
###xml 531 539 <span type="species:ncbi:9606">patients</span>
TLRs mainly signal through the adapter protein MyD88 via activation of NF-kappaB and mitogen-activated protein kinase, resulting in the increased transcription of inflammation-related genes, such as those encoding IL-1, TNF-alpha, MCP-1 [3]. In addition, a MyD88-independent pathway involving Trif is essential to TLR3 and TLR4 signalling and induces IFNbeta [3]. In the previous study [4], we showed that activation of the MyD88 pathway is increased in type 1 diabetic patients. In the present study, we show that type 1 diabetic patients have high circulating levels of IFNbeta (downstream indicator of non-MyD88 pathway activation).
###end p 33
###begin p 34
In summary, in this paper we report the novel observation that there is significant elevation of endogenous ligands of TLR2 and TLR4 in type 1 diabetes, which, in concert with hyperglycaemia, contributes to the increase in TLR2 and TLR4 signalling that results in the proinflammatory state of type 1 diabetes. In future studies, we will test levels of endogenous ligands and TLR2 and TLR4 expression and signalling in type 2 diabetes, which is also a proinflammatory state.
###end p 34
###begin title 35
Acknowledgements
###end title 35
###begin p 36
Grant support from the Juvenile Diabetes Research Foundation (JDRF) (no. 1-2007-585 to I. Jialal) and the National Institutes of Health (no. DK69801 to S. Devaraj; no. K24AT00596 to I. Jialal). Technical support from C. Duncan-Staley.
###end p 36
###begin p 37
###xml 0 19 0 19 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Duality of interest</bold>
Duality of interest The authors declare that there is no duality of interest associated with this manuscript.
###end p 37
###begin p 38
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 38
###begin title 39
References
###end title 39
###begin article-title 40
Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus
###end article-title 40
###begin article-title 41
###xml 63 71 <span type="species:ncbi:9606">patients</span>
Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes
###end article-title 41
###begin article-title 42
Toll-like receptors and atherosclerosis: key contributors in disease and health?
###end article-title 42
###begin article-title 43
###xml 75 83 <span type="species:ncbi:9606">patients</span>
Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state
###end article-title 43
###begin article-title 44
Endogenous TLR ligands and autoimmunity
###end article-title 44
###begin article-title 45
Heat shock proteins: linking danger and pathogen recognition
###end article-title 45
###begin article-title 46
High mobility group box 1 protein interacts with multiple Toll-like receptors
###end article-title 46
###begin article-title 47
Growth arrest-specific gene 6 is involved in glomerular hypertrophy in the early stage of diabetic nephropathy
###end article-title 47
###begin article-title 48
Acute modulation of toll-like receptors by insulin
###end article-title 48
###begin article-title 49
###xml 65 70 <span type="species:ncbi:9606">human</span>
Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes
###end article-title 49
###begin title 50
Abbreviations
###end title 50
###begin p 51
Growth arrest-specific 6
###end p 51
###begin p 52
High-mobility group box 1
###end p 52
###begin p 53
Heat shock protein
###end p 53
###begin p 54
Interferon-beta
###end p 54
###begin p 55
Mean fluorescence intensity of 10,000 cells
###end p 55
###begin p 56
Myeloid differentiation primary response 88
###end p 56
###begin p 57
Nuclear factor kappaB
###end p 57
###begin p 58
Receptor for advanced glycation end-products
###end p 58
###begin p 59
Toll-like receptor
###end p 59

